0
0

Chapter 4. Attention-Deficit/Hyperactivity Disorder

Joseph Biederman, M.D.; Thomas Spencer, M.D.; Timothy Wilens, M.D.
DOI: 10.1176/appi.books.9781585622986.250836

Sections

Excerpt

Attention-deficit/hyperactivity disorder (ADHD) is defined in DSM-IV-TR (American Psychiatric Association 2000) as a behavioral disorder of childhood onset (by the age of 7 years) characterized by symptoms of inattentiveness and impulsivity/hyperactivity. Based on the type of symptoms that predominate, DSM-IV-TR recognizes a combined type in which both inattention and hyperactivity/impulsivity symptoms are present, a predominantly inattentive subtype, and a predominantly hyperactive/impulsive subtype. In addition, DSM-IV-TR also recognizes the category of ADHD not otherwise specified (NOS) for individuals presenting with atypical features.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Table Reference Number
Table 4–1. Stimulants used in the pharmacotherapy of attention-deficit/hyperactivity disorder
Table Reference Number
Table 4–2. Nonstimulant agents used in the pharmacotherapy of attention-deficit/hyperactivity disorder 

References

Abramowicz M: Sudden death in children treated with a tricyclic antidepressant, in The Medical Letter on Drugs and Therapeutics. The Medical Letter, 1990, p 53
 
Adler L, Resnick S, Kunz M, et al: Open-label trial of venlafaxine in attention deficit disorder. New Clinical Drug Evaluation Unit Program, Orlando, FL, 1995
 
Adler LA, Spencer TJ, Milton DR, et al: Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry 66:294–299, 2005
[PubMed]
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000
 
Barkley RA: A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 18:137–165, 1977
[PubMed]
 
Barrickman L, Noyes R, Kuperman S, et al: Treatment of ADHD with fluoxetine: a preliminary trial. J Am Acad Child Adolesc Psychiatry 30:762–767, 1991
[PubMed]
 
Barrickman L, Perry P, Allen A, et al: Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:649–657, 1995
[PubMed]
 
Bergman A, Winters L, Cornblatt B: Methylphenidate: effects on sustained attention, in Ritalin: Theory and Patient Management. Edited by Greenhill LL, Osman B. New York, Mary Ann Liebert, 1991, pp 223–231
 
Biederman J, Gastfriend DR, Jellinek MS: Desipramine in the treatment of children with attention deficit disorder. J Clin Psychopharmacol 6:359–363, 1986
[PubMed]
 
Biederman J, Baldessarini RJ, Wright V, et al: A double-blind placebo controlled study of desipramine in the treatment of ADD, I: efficacy. J Am Acad Child Adolesc Psychiatry 28:777–784, 1989
[PubMed]
 
Biederman J, Faraone SV, Keenan K, et al: Further evidence for family genetic risk factors in attention deficit hyperactivity disorder: patterns of comorbidity in probands and relatives in psychiatrically and pediatrically referred samples. Arch Gen Psychiatry 49:728–738, 1992
[PubMed]
 
Biederman J, Baldessarini RJ, Wright V, et al: A double-blind placebo controlled study of desipramine in the treatment of attention deficit disorder, III: lack of impact of comorbidity and family history factors on clinical response. J Am Acad Child Adolesc Psychiatry 32:199–204, 1993
[PubMed]
 
Biederman J, Milberger S, Faraone S, et al: Family environmental risk factors for attention deficit hyperactivity disorder: a test of Rutter's indicators of adversity. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, October 1994
 
Biederman J, Thisted R, Greenhill L, et al: Estimation of the association between desipramine and the risk for sudden death in 5- to14-year-old children. J Clin Psychiatry 56:87–93, 1995a
 
Biederman J, Wilens T, Mick E, et al: Psychoactive substance use disorder in adults with attention deficit hyperactivity disorder: effects of ADHD and psychiatric comorbidity. Am J Psychiatry 152:1652–1658, 1995b
 
Biederman J, Wilens T, Mick E, et al: Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104:E20, 1999
 
Biederman J, Lopez FA, Boellner SW, et al: A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 in children with attention deficit hyperactivity disorder. Pediatrics 110:258–266, 2002a
 
Biederman J, Quinn D, Wigal S, et al: Methylphenidate hydrochloride extended-release capsules: once-daily therapy for ADHD (NR334), in 2002 New Research Program and Abstracts, American Psychiatric Association 155th Annual Meeting, Philadelphia, PA, May 18–23, 2002. Washington, DC, American Psychiatric Association, 2002b, p 29
 
Biederman J, Spencer TJ, Wilens TE, et al: Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectrums 10 (12 suppl 20):16–25, 2005a
 
Biederman J, Swanson J, Wigal S, et al: Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 116:777–784, 2005b
 
Brown RT, Wynne ME, Slimmer LW: Attention deficit disorder and the effect of methylphenidate on attention, behavioral, and cardiovascular functioning. J Clin Psychiatry 45:473–476, 1984
[PubMed]
 
Buitelaar J, van de Gaag R, Swaab-Barneveld H, et al: Pindolol and methylphenidate in children with attention deficit hyperactivity disorder. J Child Psychol Psychiatry 37:587–595, 1996
[PubMed]
 
Bymaster FP, Katner JS, Nelson DL, et al: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699–711, 2002
[PubMed]
 
Casat CD, Pleasants DZ, Van Wyck Fleet J: A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmacol Bull 23:120–122, 1987
[PubMed]
 
Casat CD, Pleasants DZ, Schroeder DH, et al: Bupropion in children with attention deficit disorder. Psychopharmacol Bull 25:198–201, 1989
[PubMed]
 
Castellanos F, Giedd J, Marsh W, et al: Quantitative brain magnetic resonance imaging in attention deficit hyperactivity disorder. Arch Gen Psychiatry 53:607–616, 1996
[PubMed]
 
Castellanos FX, Lee PP, Sharp W, et al: Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 288:1740–1748, 2002
[PubMed]
 
Chandler MC, Lopez FA, Biederman J: Long-term safety and efficacy of Adderall extended release in children with ADHD (NR45), in 2002 New Research Program and Abstracts, American Psychiatric Association 155th Annual Meeting, Philadelphia, PA, May 18–23, 2002. Washington, DC, American Psychiatric Association, 2002, p 19
 
Chappell P, Riddle M, Scahill L, et al: Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 34:1140–1146, 1995
[PubMed]
 
Comings DE, Comings BG: Tourette's syndrome and attention deficit disorder, in Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment. Edited by Cohen DJ, Bruun RD, Leckman JF. New York, John Wiley & Sons, 1988, pp 119–136
 
Conners CK, Casat CD, Gualtieri CT, et al: Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 35:1314–1321, 1996
[PubMed]
 
Conners CK, Casat C, Coury D, et al: Randomized trial of dex-methylphenidate (d-MPH) and d,l-MH in children with ADHD. Paper presented at: The 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Honolulu, HI, October 2001
 
Connor D, Ozbayrak K, Benjamin S, et al: A pilot study of nadolol for overt aggression in developmentally delayed individuals. J Am Acad Child Adolesc Psychiatry 36:826–834, 1997
[PubMed]
 
Cox W: An indication for the use of imipramine in attention deficit disorder. Am J Psychiatry 139:1059–1060, 1982
[PubMed]
 
DeVane C: Differential pharmacology of newer antidepressants. J Clin Psychiatry 59:85–93, 1998
[PubMed]
 
Dillon DC, Salzman IJ, Schulsinger DA: The use of imipramine in Tourette's syndrome and attention deficit disorder: case report. J Clin Psychiatry 46:348–349, 1985
[PubMed]
 
Ding Y, Fowler J, Volkow N, et al: Carbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain. J Nucl Med 36:2298–2305, 1995
[PubMed]
 
Donnelly M, Zametkin AJ, Rapoport JL, et al: Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin Pharmacol Ther 39:72–81, 1986
[PubMed]
 
Donnelly M, Rapoport JL, Potter WZ, et al: Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Arch Gen Psychiatry 46:205–212, 1989
[PubMed]
 
Douglas V, Barr R, Amin K, et al: Dosage effects and individual responsivity to methylphenidate in attention deficit disorder. J Child Psychol Psychiatry 29:453–475, 1988
[PubMed]
 
Engber TM, Koury EJ, Dennis SA, et al: Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett 241:95–98, 1998
[PubMed]
 
Faraone SV: Genetics of childhood disorders, XX: ADHD, part 4: is ADHD genetically heterogeneous? J Am Acad Child Adolesc Psychiatry 39:1455–1457, 2000
[PubMed]
 
Faraone SV, Biederman J: The neurobiology of attention deficit hyperactivity disorder, in Neurobiology of Mental Illness. Edited by Charney DS, Nestler EJ, Bunney BS. New York, Oxford University Press, 1999, pp 788–801
 
Faraone SV, Biederman J, Krifcher Lehman B, et al: Intellectual performance and school failure in children with attention deficit hyperactivity disorder and in their siblings. J Abnorm Psychol 102:616–623, 1993
[PubMed]
 
Findling R, Schwartz M, Flannery D, et al: Venlafaxine in adults with ADHD: an open trial. J Clin Psychiatry 57:184–189, 1996
[PubMed]
 
Fung YK: Postnatal behavioural effects of maternal nicotine exposure in rats. J Pharm Pharmacol 40:870–872, 1988
[PubMed]
 
Fung YK, Lau YS: Effects of prenatal nicotine exposure on rat striatal dopaminergic and nicotinic systems. Pharmacol Biochem Behav 33:1–6, 1989
[PubMed]
 
Gadow K, Sverd J, Sprafkin J, et al: Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 52:444–455, 1995 [published erratum appears in Arch Gen Psychiatry 52:836, 1995]
[PubMed]
 
Gadow KD, Nolan EE, Sverd J: Methylphenidate in hyperactive boys with comorbid tic disorder, II: short-term behavioral effects in school settings. J Am Acad Child Adolesc Psychiatry 31:462–471, 1992
[PubMed]
 
Garfinkel BD, Wender PH, Sloman L, et al: Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Adolesc Psychiatry 22:343–348, 1983
[PubMed]
 
Gastfriend DR, Biederman J, Jellinek MS: Desipramine in the treatment of attention deficit disorder in adolescents. Psychopharmacol Bull 21:144–145, 1985
[PubMed]
 
Gittelman R: Childhood disorders, in Drug Treatment of Adult and Child Psychiatric Disorders. Edited by Klein D, Quitkin F, Rifkinet A, et al. Baltimore, MD, Williams & Wilkins, 1980, pp 576–756
 
Gittelman-Klein R: Pilot clinical trial of imipramine in hyperkinetic children, in Clinical Use of Stimulant Drugs in Children. Edited by Conners CK. The Hague, Netherlands, Excerpta Medica, 1974, pp 192–201
 
Gittelman-Klein R: Pharmacotherapy of childhood hyperactivity: an update, in Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York, Raven, 1987, pp 1215–1224
 
Goldman L, Genel M, Bezman R, et al: Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 279:1100–1107, 1998
[PubMed]
 
Greenblatt D, Moltke L, Harmatz J, et al: Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry 59:19–27, 1998
[PubMed]
 
Greenhill L, Halperin J, Abikoff H: Stimulant medications. J Am Acad Child Adolesc Psychiatry 38:503–512, 1998
 
Greenhill LL, Findling RL, Swanson JM: A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 109:E39, 2002
 
Greenhill LL, Ball R, Levine AJ, et al: Extended-release dexmethylphenidate in children and adolescents with ADHD. Paper presented at: The 158th Annual Meeting of the American Psychiatric Association, Atlanta, GA, May 21–26, 2005
 
Gross M: Imipramine in the treatment of minimal brain dysfunction in children. Psychosomatics 14:283–285, 1973
[PubMed]
 
Gross M: Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine. J Pediatrics 58:423–431, 1976
[PubMed]
 
Gualtieri CT, Evans RW: Motor performance in hyperactive children treated with imipramine. Percept Mot 66:763–769, 1988
[PubMed]
 
Gunning B: A controlled trial of clonidine in hyperkinetic children. Unpublished doctoral dissertation, Department of Child and Adolescent Psychiatry, Academic Hospital Rotterdam–Sophia Children's Hospital, Rotterdam, The Netherlands, 1992
 
Heil SH, Holmes HW, Bickel WK, et al: Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67:149–156, 2002
[PubMed]
 
Hoge SK, Biederman J: A case of Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine. J Clin Psychiatry 47:478–479, 1986
[PubMed]
 
Hornig-Rohan M, Amsterdam J: Venlafaxine vs. stimulant therapy in patients with dual diagnoses of ADHD and depression (poster #92). New Clinical Drug Evaluation Unit Program, Orlando, FL, 1995
 
Horrigan JP, Barnhill LJ: Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 5:215–223, 1995
 
Huessy H, Wright A: The use of imipramine in children's behavior disorders. Acta Paedopsychiatrie 37:194–199, 1970
[PubMed]
 
Hunt R, Arnsten A, Asbell M: An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:50–54, 1995
[PubMed]
 
Hunt RD: Treatment effects of oral and transdermal clonidine in relation to methylphenidate: an open pilot study in ADD-H. Psychopharmacol Bull 23:111–114, 1987
[PubMed]
 
Hunt RD, Minderaa RB, Cohen DJ: Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 24:617–629, 1985
[PubMed]
 
Hunt RD, Capper L, O'Connell P: Clonidine in child and adolescent psychiatry. J Child Adolesc Psychopharmacol 1:87–102, 1990
 
Hurt R, Sachs DP, Glover ED, et al: A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195–1202, 1997
[PubMed]
 
Jensen PS: National Institute of Mental Health multimodal treatment study. Scientific Proceedings of the Annual Meeting of the American Academy of Child Adolescent Psychiatry, San Francisco, CA, October 1998
 
Johns JM, Louis TM, Becker RF, et al: Behavioral effects of prenatal exposure to nicotine in guinea pigs. Neurobehav Toxicol Teratol 4:365–369, 1982
[PubMed]
 
Jones GM, Sahakian BJ, Levy R, et al: Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl) 108:485–494, 1992
[PubMed]
 
Klein R, Mannuzza S: Hyperactive boys almost grown up, III: methylphenidate effects on ultimate height. Arch Gen Psychiatry 45:1131–1134, 1988
[PubMed]
 
Kratochvil CJ, Bohac D, Harrington M, et al: An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11:167–170, 2001
[PubMed]
 
Kupietz SS, Balka EB: Alterations in the vigilance performance of children receiving amitriptyline and methylphenidate pharmacotherapy. Psychopharmacology (Berl) 50:29–33, 1976
[PubMed]
 
Kupietz SS, Winsberg BG, Richardson E, et al: Effects of methylphenidate dosage in hyperactive reading-disabled children, I: behavior and cognitive performance effects. J Am Acad Child Adolesc Psychiatry 27:70–77, 1988
[PubMed]
 
Leckman JF, Hardin MT, Riddle MA, et al: Clonidine treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 48:324–328, 1991
[PubMed]
 
Levin ED, Conners CK, Sparrow E, et al: Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 123:55–63, 1996
[PubMed]
 
Lowe TL, Cohen DJ, Detlor J: Stimulant medications precipitate Tourette's syndrome. JAMA 247:1168–1169, 1982
[PubMed]
 
Malhotra S, Santosh PJ: An open clinical trial of buspirone in children with attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 37:364–371, 1998
[PubMed]
 
Mattes JA: Propranolol for adults with temper outbursts and residual attention deficit disorder. J Clin Psychopharmacol 6:299–302, 1986
[PubMed]
 
Mattes JA, Gittelman R: Growth of hyperactive children on maintenance regimen of methylphenidate. Arch Gen Psychiatry 40:317–321, 1983
[PubMed]
 
McCracken JT, Biederman J, Greenhill LL, et al: Analog classroom assessment of SLI381 for treatment of ADHD (P26), in Abstracts of the American Academy of Child and Adolescent Psychiatry Annual Meeting, New York, October 24–29, 2000, p 104
 
Meck WH, Church RM: Cholinergic modulation of the content of temporal memory. Behav Neurosci 101:457–464, 1987
[PubMed]
 
Mereu G, Yoon K, Gessa G, et al: Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur J Pharmacol 141:395–399, 1987
[PubMed]
 
Michelson D, Faries D, Wernicke J, et al: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:E83, 2001
 
Michelson D, Adler L, Spencer T, et al: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112–120, 2003
[PubMed]
 
Milberger S, Biederman J, Faraone S, et al: Is maternal smoking during pregnancy a risk factor for attention deficit hyperactivity disorder in children? Am J Psychiatry 153:1138–1142, 1996
[PubMed]
 
Milberger S, Biederman J, Faraone S, et al: Pregnancy delivery and infancy complications and ADHD: issues of gene-environment interactions. Biol Psychiatry 41:65–75, 1997a
 
Milberger S, Biederman J, Faraone SV, et al: Attention deficit hyperactivity disorder is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 36:37–44, 1997b
 
Myrick H, Malcolm R, Taylor B, et al: Modafinil: preclinical, clinical, and post-marketing surveillance—a review of abuse liability issues. Ann Clin Psychiatry 16:101–109, 2004
[PubMed]
 
National Institute of Mental Health: Alternative Pharmacology of ADHD (NIMH report). Rockville, MD, National Institute of Mental Health, 1996
 
Nemeroff C, DeVane L, Pollock B: Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311–320, 1996
[PubMed]
 
Olvera RL, Pliszka SR, Luh J, et al: An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 6:241–250, 1996
[PubMed]
 
Palumbo D: Impact of ADHD treatment once-daily OROS formulation of MPH on tics (NR340), in 2002 New Research Program and Abstracts, American Psychiatric Association 155th Annual Meeting, Philadelphia, PA, May 18–23, 2002. Washington, DC, American Psychiatric Association, 2002, p 30
 
Parrott AC, Winder G: Nicotine chewing gum (2 mg, 4 mg) and cigarette smoking: comparative effects on vigilance and heart rate. Psychopharmacology (Berl) 97:257–261, 1989
[PubMed]
 
Peeke SC, Peeke HV: Attention, memory, and cigarette smoking. Psychopharmacology (Berl) 84:205–216, 1984
[PubMed]
 
Pelham WE, Bender ME, Caddell J, et al: Methylphenidate and children with attention deficit disorder. Arch Gen Psychiatry 42:948–952, 1985
[PubMed]
 
Pelham WE, Gnagy EM, Burrows-Maclean L, et al: Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105, 2001
 
Pentikis HS, Simmons RD, Benedict MF, et al: Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry 41:443–449, 2002
[PubMed]
 
Pomerleau O, Downey K, Stelson F, et al: Cigarette smoking in adult patients diagnosed with ADHD. J Subst Abuse 7:373–378, 1996
 
Potter A, Corwin J, Lang J, et al: Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl) 142:334–342, 1999
[PubMed]
 
Prince J, Wilens T, Biederman J, et al: Clonidine for ADHD related sleep disturbances: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 35:599–605, 1996
[PubMed]
 
Prince J, Wilens T, Biederman J, et al: A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. Paper presented at: Scientific Proceedings of the American Academy of Child and Adolescent Psychiatrists, Chicago, IL, 1999
 
Quinn PO, Rapoport JL: One-year follow-up of hyperactive boys treated with imipramine or methylphenidate. Am J Psychiatry 132:241–245, 1975
[PubMed]
 
Quitkin FM, Harrison W, Stewart JW, et al: Response to phenelzine and imipramine in placebo nonresponders with atypical depression. Arch Gen Psychiatry 48:319–323, 1991
[PubMed]
 
Rapoport JL, Quinn P, Bradbard G, et al: Imipramine and methylphenidate treatment of hyperactive boys: a double-blind comparison. Arch Gen Psychiatry 30:789–793, 1974
[PubMed]
 
Rapport MD, Jones JT, DuPaul GJ, et al: Attention deficit disorder and methylphenidate: group and single-subject analyses of dose effects on attention in clinic and classroom settings. J Clin Child Psychol 16:329–338, 1987
 
Rapport MD, Stoner G, DuPaul GJ, et al: Attention deficit disorder and methylphenidate: a multilevel analysis of dose-response effects on children's impulsivity across settings. J Am Acad Child Adolesc Psychiatry 27:60–69, 1988
[PubMed]
 
Rapport MD, DuPaul GJ, Kelly KL: Attention deficit hyperactivity disorder and methylphenidate: the relationship between gross body weight and drug response in children. Psychopharmacol Bull 25:285–290, 1989a
 
Rapport MD, Quinn SO, DuPaul GJ, et al: Attention deficit disorder with hyperactivity and methylphenidate: the effects of dose and mastery level on children's learning performance. J Abnorm Child Psychol 17:669–689, 1989b
 
Rapport M, Carlson G, Kelly K, et al: Methylphenidate and desipramine in hospitalized children, I: separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 32:333–342, 1993
[PubMed]
 
Ratey J, Greenberg M, Lindem K: Combination of treatments for attention deficit disorders in adults. J Nerv Ment Dis 176:699–701, 1991
 
Reimherr FW, Wender PH, Wood DR, et al: An open trial of l-tyrosine in the treatment of attention deficit disorder, residual type. Am J Psychiatry 144:1071–1073, 1987
[PubMed]
 
Reimherr F, Hedges D, Strong R, et al: An open-trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. New Clinical Drug Evaluation Unit Program, Orlando, FL, 1995
 
Riddle MA, Hardin MT, Cho SC, et al: Desipramine treatment of boys with attention-deficit hyperactivity disorder and tics: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 27:811–814, 1988
[PubMed]
 
Riddle MA, Nelson JC, Kleinman CS, et al: Sudden death in children receiving Norpramin: a review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 30:104–108, 1991
[PubMed]
 
Safer DJ, Allen RP, Barr E: Depression of growth in hyperactive children on stimulant drugs. N Engl J Med 287:217–220, 1972
[PubMed]
 
Satterfield JH, Cantwell DP, Schell A, et al: Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry 36:212–217, 1979
[PubMed]
 
Scahill L, Chappell PB, Kim YS, et al: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 158:1067–1074, 2001
[PubMed]
 
Schachar R, Tannock R: Childhood hyperactivity and psychostimulants: a review of extended treatment studies. J Child Adolesc Psychopharmacol 3:81–97, 1993
 
Silva R, Munoz D, Alpert M: Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: a meta-analysis. J Am Acad Child Adolesc Psychiatry 35:352–358, 1996
[PubMed]
 
Singer S, Brown J, Quaskey S, et al: The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 95:74–81, 1995
[PubMed]
 
Spencer T: ADHD treatment with a once-daily formulation of MPH: effect on growth (NR344), in 2002 New Research Program and Abstracts, American Psychiatric Association 155th Annual Meeting, Philadelphia, PA, May 18–23, 2002. Washington, DC, American Psychiatric Association, 2002, p 30
 
Spencer T, Biederman J, Kerman K, et al: Desipramine in the treatment of children with tic disorder or Tourette's syndrome and attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 32:354–360, 1993a
 
Spencer T, Biederman J, Wilens T, et al: Nortriptyline in the treatment of children with attention deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 32:205–210, 1993b
 
Spencer T, Wilens T, Biederman J, et al: A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 52:434–443, 1995
[PubMed]
 
Spencer TJ, Biederman J, Wilens T, et al: Pharmacotherapy of attention deficit hyperactivity disorder across the life cycle: a literature review. J Am Acad Child Adolesc Psychiatry 35:409–432, 1996
[PubMed]
 
Spencer T, Biederman J, Wilens T: Pharmacotherapy of ADHD: a life span perspective, in American Psychiatric Press Review of Psychiatry. Edited by Oldham J, Riba M. Washington, DC, American Psychiatric Association, 1997, pp 87–128
 
Spencer T, Biederman J, Wilens T: Growth deficits in children with attention deficit hyperactivity disorder. Pediatrics 102:501–506, 1998a
 
Spencer T, Biederman J, Wilens T, et al: Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693–695, 1998b
 
Spencer T, Biederman J, Wilens TE, et al: Adults with attention-deficit/hyperactivity disorder: a controversial diagnosis. J Clin Psychiatry 59:59–68, 1998c
 
Spencer T, Biederman J, Coffey B, et al: The 4-year course of tic disorders in boys with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:842–847, 1999
[PubMed]
 
Spencer T, Swanson J, Weidenman M, et al: Pharmacodynamic profile of Ritalin LA, a new extended-release dosage form of Ritalin, in children with ADHD. Paper presented at: The 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, October 24–29, 2000
 
Spencer T, Biederman J, Heiligenstein J, et al: An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11:251–265, 2001
[PubMed]
 
Spencer T, Biederman J, Coffey B, et al: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 59:649–656, 2002a
 
Spencer T, Heiligenstein J, Biederman J, et al: Results from two proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140–1147, 2002b
 
Spencer T, Biederman J, Abikoff H, et al: Efficacy of dexmethylphenidate extended-release capsules in adults with attention deficit/hyperactivity disorder. Paper presented at: The 157th Annual Meeting of the American Psychiatric Association, New York, May 1–6, 2004
 
Spencer T, Newcorn J, Kratochvil C, et al: Effects of atomoxetine on growth after 2-year treatment in pediatric patients with ADHD. Pediatrics 116:E74–E80, 2005
 
Steingard R, Biederman J, Spencer T, et al: Comparison of clonidine response in the treatment of attention deficit hyperactivity disorder with and without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 32:350–353, 1993
[PubMed]
 
Swanson J, Agler D, Fineberg E, et al: University of California, Irvine, laboratory school protocol for pharmacokinetic and pharmacodynamic studies, in Ritalin: Theory and Practice, 2nd Edition. Edited by Greenhill L, Osman BB. Larchmont, NY, Mary Ann Liebert, 2000, pp 405–430
 
Swanson J, Greenhill LL, Biederman J: Modafinil in children with ADHD: a randomized, placebo-controlled study. Paper presented at: The 157th Annual Meeting of the American Psychiatric Association, Washington, DC, May 2004
 
Tannock R, Schachar RJ, Carr RP, et al: Dose-response effects of methylphenidate on academic performance and overt behavior in hyperactive children. Pediatrics 84:648–657, 1989
[PubMed]
 
Taylor FB: Comparing guanfacine and dextroamphetamine for adult ADHD: efficacy and implications (NR658), in 2000 New Research Program and Abstracts, American Psychiatric Association 153rd Annual Meeting, Chicago, IL, May 13–18, 2000. Washington, DC, American Psychiatric Association, 2000
 
Tourette's Syndrome Study Group: Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58:527–536, 2002
[PubMed]
 
Volkow ND, Wang G, Fowler JS, et al: Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21:RC121, 2001
 
Watter N, Dreyfuss FE: Modifications of hyperkinetic behavior by nortriptyline. Virginia Medical Monthly 100:123–126, 1973
[PubMed]
 
Weisler RH, Biederman J, Spencer T: Mixed amphetamine salts extended release (Adderall XR) in the treatment of adult attention-deficit/hyperactivity disorder: a randomized, controlled trial (NR647), in 2004 New Research Program and Abstracts, American Psychiatric Association 157th Annual Meeting, New York, May 1–6, 2004. Washington, DC, American Psychiatric Association, 2004
 
Wender PH, Reimherr FW: Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 147:1018–1020, 1990
[PubMed]
 
Werry J: Imipramine and methylphenidate in hyperactive children. J Child Psychol Psychiatry 21:27–35, 1980
[PubMed]
 
Wesnes K, Warburton DM: The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology (Berl) 82:338–342, 1984
[PubMed]
 
West S, Johnson DE, Wigal S, et al: Withdrawal trial of dex-methylphenidate (Focalin) in children with ADHD (NR341), in 2002 New Research Program and Abstracts, American Psychiatric Association 155th Annual Meeting, Philadelphia, PA, May 18–23, 2002. Washington, DC, American Psychiatric Association, 2002, p 30
 
Westfall TC, Grant H, Perry H: Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. Gen Pharmacol 14:321–325, 1983
[PubMed]
 
Wilens TE, Biederman J: The stimulants. Psychiatr Clin North Am 15:191–222, 1992
[PubMed]
 
Wilens TE, Spencer TJ: Combining methylphenidate and clonidine: a clinically sound medication option. J Am Child Adolesc Psychiatry 38:614–622, 1999
[PubMed]
 
Wilens TE, Biederman J, Geist DE, et al: Nortriptyline in the treatment of attention deficit hyperactivity disorder: a chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 32:343–349, 1993
[PubMed]
 
Wilens TE, Biederman JB, Mick E, et al: A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 183:48–50, 1995
[PubMed]
 
Wilens TE, Biederman J, Abrantes A, et al: A naturalistic assessment of protriptyline for attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 35:1485–1490, 1996a
 
Wilens TE, Biederman J, Prince J, et al: Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 153:1147–1153, 1996b
 
Wilens TE, Biederman J, Spencer TJ, et al: Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 19:257–264, 1999a
 
Wilens TE, Biederman J, Spencer TJ, et al: A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 156:1931–1937, 1999b
 
Wilens TE, Spencer T, Biederman J, et al: A controlled trial of bupropion SR for attention deficit hyperactivity disorder in adults (poster #29). New Clinical Drug Evaluation Unit Program, Boca Raton, FL, 1999c
 
Wilens TE, Pelham WE, Stein M, et al: ADHD treatment with a once-daily formulation of methylphenidate: a 2-year study (NR44), in 2002 New Research Program and Abstracts, American Psychiatric Association 155th Annual Meeting, Philadelphia, PA, May 18–23, 2002. Washington, DC, American Psychiatric Association, 2002, p 19
 
Wilson HK: Effect of extended-release stimulant-based medications on neuropsychological functioning among adolescents with attention-deficit/hyperactivity disorder. Arch Clin Neuropsychol 21:797–807, 2006
[PubMed]
 
Winsberg BG, Bialer I, Kupietz S, et al: Effects of imipramine and dextroamphetamine on behavior of neuropsychiatrically impaired children. Am J Psychiatry 128:1425–1431, 1972
[PubMed]
 
Wolraich M, Greenhill LL, Pelham W, et al: Randomized controlled trial of OROS methylphenidate qd in children with attention deficit/hyperactivity disorder. Pediatrics 108:883–892, 2001
[PubMed]
 
Yepes LE, Balka EB, Winsberg BG, et al: Amitriptyline and methylphenidate treatment of behaviorally disordered children. J Child Psychol Psychiatry 18:39–52, 1977
[PubMed]
 
Zametkin AJ, Rapoport JL: Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years? J Am Acad Child Adolesc Psychiatry 26:676–686, 1987
[PubMed]
 
Zametkin A, Rapoport JL, Murphy DL, et al: Treatment of hyperactive children with monoamine oxidase inhibitors, I: clinical efficacy. Arch Gen Psychiatry 42:962–966, 1985
[PubMed]
 
Zametkin AJ, Nordahl TE, Gross M, et al: Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med 323:1361–1366, 1990
[PubMed]
 
Zhang S, Faries DE, Vowles M, et al: ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument. Int J Methods Psychiatr Res 14(4):186–201, 2005
[PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 36.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 2.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 3.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 6.  >
Topic Collections
Psychiatric News
PubMed Articles
Medication: the smart-pill oversell. Nature 2014;506(7487):146-8.doi:10.1038/506146a.
Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med 2014;370(9):838-46.doi:10.1056/NEJMcp1307215.
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation